{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:13:58Z","timestamp":1789953238737,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12967-015-0706-7","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T02:54:29Z","timestamp":1446087269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera"],"prefix":"10.1186","volume":"13","author":[{"given":"Arne","family":"Homann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"R\u00f6ckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Kromminga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Jappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"706_CR1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","volume":"10","author":"AC Chan","year":"2010","unstructured":"Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301\u201316.","journal-title":"Nat Rev Immunol"},{"key":"706_CR2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","volume":"9","author":"PA Schouwenburg Van","year":"2013","unstructured":"Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164\u201372.","journal-title":"Nat Rev Rheumatol"},{"key":"706_CR3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","volume":"9","author":"M Feldmann","year":"2003","unstructured":"Feldmann M, Maini RN. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9:1245\u201350.","journal-title":"Nat Med"},{"key":"706_CR4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future: therapeutic antibodies: an update. Br J Pharmacol. 2009;157:220\u201333.","journal-title":"Br J Pharmacol"},{"key":"706_CR5","first-page":"335","volume":"18","author":"RT Purcell","year":"2008","unstructured":"Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008;18:335\u201342.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"706_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","volume":"34","author":"C Steenholdt","year":"2011","unstructured":"Steenholdt C, Svenson M, Bendtzen K, Thomsen O \u00f8, Brynskov J, Ainsworth MA. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease: severe infusion reactions to infliximab in IBD. Aliment Pharmacol Ther. 2011;34:51\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"706_CR7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","volume":"65","author":"A Vultaggio","year":"2010","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657\u201361.","journal-title":"Allergy"},{"key":"706_CR8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1208\/s12248-013-9492-4","volume":"15","author":"L Xue","year":"2013","unstructured":"Xue L, Fiscella M, Rajadhyaksha M, Goyal J, Holland C, Gorovits B, Morimoto A. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Scientists. AAPS J. 2013;15:852\u20135.","journal-title":"AAPS J"},{"key":"706_CR9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose. N Engl J Med. 2008;358:1109\u201317.","journal-title":"N Engl J Med"},{"key":"706_CR10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jim.2005.10.007","volume":"308","author":"JA Lofgren","year":"2006","unstructured":"Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J Immunol Methods. 2006;308:101\u20138.","journal-title":"J Immunol Methods"},{"key":"706_CR11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429\u201335.","journal-title":"Clin Rheumatol"},{"key":"706_CR12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/annrheumdis-2012-201445","volume":"72","author":"PA Schouwenburg van","year":"2013","unstructured":"van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EEL, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72:104\u20139.","journal-title":"Ann Rheum Dis"},{"key":"706_CR13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/apt.12330","volume":"37","author":"C Steenholdt","year":"2013","unstructured":"Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1172\u201383.","journal-title":"Aliment Pharmacol Ther"},{"key":"706_CR14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1208\/s12248-013-9497-z","volume":"15","author":"L Xue","year":"2013","unstructured":"Xue L, Rup B. Evaluation of Pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J. 2013;15:893\u20136.","journal-title":"AAPS J"},{"key":"706_CR15","first-page":"256","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies. Residual Immunogenicity Resides CDR Reg MAbs. 2010;2:256\u201365.","journal-title":"Residual Immunogenicity Resides CDR Reg MAbs"},{"key":"706_CR16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/MIB.0000000000000138","volume":"20","author":"MT Frederiksen","year":"2014","unstructured":"Frederiksen MT, Ainsworth MA, Brynskov JM, Thomsen OOM, Bendtzen KM, Steenholdt C. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014;20:1714\u201321.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"706_CR17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","volume":"74","author":"KA Schie van","year":"2014","unstructured":"Schie KA van, Hart MH, Groot ER de, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2014;74(1):311\u20134.","journal-title":"Ann Rheum Dis"},{"key":"706_CR18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-1759(98)00170-7","volume":"221","author":"A Frey","year":"1998","unstructured":"Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1998;221:35\u201341.","journal-title":"J Immunol Methods"},{"key":"706_CR19","doi-asserted-by":"crossref","first-page":"13799","DOI":"10.1074\/jbc.M112.433961","volume":"288","author":"S Liang","year":"2013","unstructured":"Liang S, Dai J, Hou S, Su L, Zhang D, Guo H, Hu S, Wang H, Rao Z, Guo Y, Lou Z. Structural basis for treating tumor necrosis factor (TNF)-associated diseases with the therapeutic antibody infliximab. J Biol Chem. 2013;288:13799\u2013807.","journal-title":"J Biol Chem"},{"issue":"7","key":"706_CR20","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.autrev.2015.02.007","volume":"14","author":"M Deehan","year":"2015","unstructured":"Deehan M, Garc\u00eas S, Kramer D, Baker MP, Rat D, Roettger Y, Kromminga A. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14(7):569\u201374.","journal-title":"Autoimmun Rev."},{"key":"706_CR21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides\u2014harmonized terminology and tactical recommendations. AAPS J. 2014;16:658\u201373.","journal-title":"AAPS J"},{"key":"706_CR22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/ACI.0b013e3283464bcd","volume":"11","author":"A Vultaggio","year":"2011","unstructured":"Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11:262\u20138.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"706_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1203\/PDR.0b013e318208451d","volume":"69","author":"M Kosma\u010d","year":"2011","unstructured":"Kosma\u010d M, Av\u010din T, Toplak N, Simonini G, Cimaz R, \u0160erbec V\u010c. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69:243\u20138.","journal-title":"Pediatr Res"},{"key":"706_CR24","doi-asserted-by":"crossref","unstructured":"Jefferis R, Lefranc M-P. Human immunoglobulin allotypes: possible implications for immunogenicity. In: MAbs. vol. 1. Austin: Landes Bioscience; 2009. p. 332.","DOI":"10.4161\/mabs.1.4.9122"},{"key":"706_CR25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FPC.0b013e32832a06bf","volume":"19","author":"C Magdelaine-Beuzelin","year":"2009","unstructured":"Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, Ohresser M, Degenne D, Dugoujon J-M, Jefferis R, Rutgeerts P, Lefranc M-P, Watier H. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics. 2009;19:383\u20137.","journal-title":"Pharmacogenet Genomics"},{"key":"706_CR26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nbt.1912","volume":"29","author":"JJL Bueren Van","year":"2011","unstructured":"Van Bueren JJL, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, et al. Anti-galactose-[alpha]-1, 3-galactose IgE from allergic patients does not bind [alpha]-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574\u20136.","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0706-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T22:26:54Z","timestamp":1498256814000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.translational-medicine.com\/content\/13\/1\/339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1186\/s12967-015-0706-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]},"article-number":"339"}}